Chester County News and Community Website
PHILADELPHIA, PA & SAN FRANCISCO, CA & SHANGHAI, China — Dispatch Bio and CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK) said they have entered into a clinical collaboration to conduct …
Dispatch Bio and CARsgen Strike China Deal to Test New CAR T Approach Read More PHILADELPHIA, PA & SAN FRANCISCO, CA — Dispatch Bio said the U.S. Food and Drug Administration has cleared its Investigational New Drug application for DISP-10, allowing the company to initiate …
FDA Clears Dispatch Bio’s Unusual Two-Step Immunotherapy for Solid Tumors Read More PHILADELPHIA, PA & SAN FRANCISCO, CA — Dispatch Bio has released new preclinical data showing encouraging progress for its lead therapeutic program, DISP-10, a first-of-its-kind combination approach designed to make …
New Playbook for Solid Tumors? Dispatch Bio Unveils Promising Preclinical Results Read More
PHILADELPHIA, PA & SAN FRANCISCO, CA — Dispatch Bio has entered into a clinical supply and collaboration agreement with Bristol Myers Squibb (BMS) to advance a first-of-its-kind solid tumor program, …
Breakthrough Team-Up? New CAR T Partnership Targets 90% of Solid Tumors Read More
PHILADELPHIA, PA & SAN FRANCISCO, CA — Dispatch Bio announced that it will present new data on its investigational cancer therapy, DISP-10, at the upcoming Society for Immunotherapy of Cancer …
Dispatch Bio to Present Novel Cancer Therapy Data at 2025 Society for Immunotherapy of Cancer Meeting Read More
PHILADELPHIA, PA & SAN FRANCISCO, CA — Dispatch Bio has appointed Mauro Avanzi, M.D., Ph.D., as Chief Medical Officer, strengthening the company’s leadership team as it prepares to advance its …
Dispatch Bio Appoints Mauro Avanzi, M.D., Ph.D., as Chief Medical Officer Read More PHILADELPHIA, PA & SAN FRANCISCO, CA — Dispatch Bio emerged from stealth this past week with a mission as ambitious as it is urgent: to develop a universal treatment for …
Dispatch Bio Launches With $216M and Bold Mission to Tackle All Solid Tumors Read More